Journal of the National Cancer Institute Advance Access originally published online on February 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(5):296-297; doi:10.1093/jnci/djn051
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
Members of New FDA Board Tied to Industry
| The first 10% of the full text of this article appears below. |
The Food and Drug Administration's most recent steps toward modernizing the drug approval process have renewed some old questions about the FDA's relationship with the industries it regulates.
Several public advocacy groups affiliated with physicians and researchers have voiced their concern over the appointment of certain members to a newly formed agency board. The groups have warned that some members may have conflicts of interest due to past or current roles as board members of pharmaceutical and biotechnology firms.
In September, Congress passed the latest version of the Prescription Drug User Fee Act—the law that established an accelerated new-drug application process funded through industry-paid fees. It included a
Reagan–Udall Foundation Board Members